Background-There is a paucity of data on the use of optimal medical therapy (OMT) in patients with complex coronary artery disease undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting (CABG) and its long-term prognostic significance. Methods and Results-The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicenter, randomized, clinical trial of patients (n=1800) with complex coronary disease randomized to revascularization with percutaneous coronary intervention or CABG. Detailed drug history was collected for all patients at discharge and at the 1-month, 6-month, 1-year, 3-year, and 5-year follow-ups. OMT was defined as the combination of at least 1 antiplatelet drug, statin, β-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Five-year clinical outcomes were stratified by OMT and non-OMT. OMT was underused in patients treated with coronary revascularization, especially CABG. OMT was an independent predictor of survival. OMT was associated with a significant reduction in mortality (hazard ratio, 0.64; 95% confidence interval, 0.48-0.85; P=0.002) and composite end point of death/myocardial infarction/stroke (hazard ratio, 0.73; 95% confidence interval, 0.58-0.92; P=0.007) at the 5-year follow-up. The treatment effect with OMT (36% relative reduction in mortality over 5 years) was greater than the treatment effect of revascularization strategy (26% relative reduction in mortality with CABG versus percutaneous coronary intervention over 5 years). On stratified analysis, all the components of OMT were important for reducing adverse outcomes regardless of revascularization strategy. Conclusions-The use of OMT remains low in patients with complex coronary disease requiring coronary intervention with percutaneous coronary intervention and even lower in patients treated with CABG. Lack of OMT is associated with adverse clinical outcomes. Targeted strategies to improve OMT use in postrevascularization patients are warranted. Clinical Trial Registration-URL: http://www.clinicaltrials.gov.
vidence-based use of optimal medical therapy (OMT) is recommended for all patients with coronary artery disease (CAD) and is the suggested initial treatment strategy for patients with stable CAD. [1] [2] [3] Nevertheless, patients with symptoms despite OMT or prognostically significant CAD typically undergo revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). [3] [4] [5] Because the progression of atherosclerosis continues after revascularization, 6, 7 all patients, especially those with complex CAD, should continue OMT after revascularization. [8] [9] [10] However, limited published literature suggests that the use of medication for secondary prevention remains suboptimal after coronary revascularization, particularly after CABG. [11] [12] [13] [14] [15] [16] This underuse of OMT might reflect medication nonadherence or issues with the healthcare system or may be related to a paucity of data, leading to an underestimation of importance of OMT and the misconception that continuing OMT may be of less value once diseased coronary arteries have been mechanically revascularized. 17, 18 Recent controversies on the use of β-blockers, generally and in noncardiac surgery, and statins may further reduce prescription or compliance, [19] [20] [21] [22] with potential consequences on long-term clinical outcomes. Therefore, a definitive evaluation of role of OMT in patients with complex CAD undergoing PCI or CABG is warranted.
A recent systematic literature review identified insufficient information on medical drug treatment in randomized, controlled trials of coronary revascularization, except for the Randomized Intervention Treatment of Angina (RITA), Coronary Angioplasty Versus Bypass Revascularisation Investigation (CABRI), and Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trials. 23 The RITA 24 and CABRI 25 trials are now historical; SYNTAX is a large (n=1800) contemporary allcomers trial of patients with complex CAD who were randomized to revascularization by PCI or CABG. Patients were followed up at 1 month, 6 months, 1 year, 3 years, and 5 years, and details of medication were recorded. 26 We aimed to use the data from SYNTAX trial to examine the use of OMT after revascularization and its association with clinical outcomes.
Methods

The SYNTAX Trial
The SYNTAX trial (http://www.clinicaltrials.gov; NCT00114972) was a prospective, multicenter, randomized trial comparing PCI and CABG for patients with complex (left main stem or 3-vessel CAD). 27 The institutional review board at each participating center approved the protocol, and all patients provided written informed consent. Eligible patients (n=1800) were randomized on a 1:1 ratio to CABG (n=897) or PCI (n=903) with TAXUS Express paclitaxel-eluting stent (Boston Scientific Corp, Natick, MA) and followed up for 5 years.
Study Medication, End Points, and Definitions
Medication status was checked for all patients at baseline (at the time of randomization), discharge, 1 month, 6 months, 1 year, 3 years, and 5 years. OMT was defined as the combination of at least 1 antiplatelet drug, statin, β-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, consistent with published literature. [28] [29] [30] The study end point was the impact of OMT on mortality at 5 years. We also investigated a composite end point (death/myocardial infarction [MI]/stroke) at the 5-year follow-up. Definitions of various end points (MI, stroke, etc) in the SYNTAX trial have been reported previously. 27 The SYNTAX score, an angiographic tool grading the complexity of CAD, and EuroSCORE (European System for Cardiac Operative Risk Evaluation), 31 a risk model based on 17 variables, were calculated prospectively. All events were adjudicated by an independent clinical event committee made up of interventional cardiologists, cardiac surgeons, and a neurologist.
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Statistical Analysis
Continuous variables are expressed as mean±SD, and categorical variables are given as counts and percentages of the total. 
Results
Prescription of Cardiac Medication in the SYNTAX Trial
In the randomized SYNTAX trial (n=1800), information on medication status was available for 1774 patients (98.6%). The proportion of patients taking various cardiac medications at different time points is shown in Figure 1 . Only 29.1% patients were taking OMT before revascularization, and 41.3% were taking OMT at the time of discharge after revascularization (PCI or CABG). OMT use was initially higher in PCI-treated patients (at discharge: PCI, 50.2%; CABG, 31.2%). However, at 5 years, only one third of patients in both treatment groups were taking OMT (PCI, 39.6%; CABG, 35.7%). A comparison of baseline characteristics between patients taking or not taking OMT revealed that patients taking OMT had more cardiac risk factors, including diabetes mellitus, hypertension, dyslipidemia, and previous MI, whereas patients not taking OMT had a different set of comorbidities, including chronic obstructive pulmonary disease, peripheral vascular disease, or higher SYNTAX score/ EuroSCORE (Table 1) .
OMT Improved Clinical Outcomes
OMT was associated with a significant reduction in 5-year mortality (hazard ratio, 0.64; 95% confidence interval, 0.48-0.85; P=0.002) and the composite end point of death/ MI/stroke (hazard ratio, 0.73; 95% confidence interval, 0.58-0.92; P=0.007; Figure 2 ). The beneficial effect of OMT was most pronounced within the first year of revascularization but was sustained throughout 5 years (P for interaction=0.481; Figure 2 ). On multivariable Cox regression analysis, OMT was an independent predictor of survival; the reduction in hazard ratio was greater with OMT than with the choice of revascularization strategy (Table 2) .
Detailed analyses of individual components of OMT revealed that all agents included in OMT were important for the entire population, as well as the PCI and CABG subgroups ( Figure 3) . Furthermore, stratified analysis across various population subgroups showed that OMT was beneficial for all patients with no significant interaction (Table 3) .
Discussion
This post hoc study of the SYNTAX trial has identified the fact that only one third of patients undergoing revascularization for complex CAD with either PCI or CABG were receiving OMT at the 5-year follow-up. Lack of OMT, in turn, was associated with adverse events, including death.
Underuse of OMT seen in our data is consistent with other studies suggesting that a significant proportion of patients with CAD and those undergoing coronary revascularization (especially CABG) remain deprived of secondary prevention therapy. [13] [14] [15] [16] [17] A large international observational registry (Reduction of Atherothrombosis for Continued Health [REACH]) of 37 154 patients with established atherosclerotic disease has shown that only 46.7% of patients at baseline and 48.2% at 1 year were taking OMT. 29 Although antiplatelet agents and lipid-lowering agents were used in more than two thirds of the SYNTAX patients, use of angiotensin-converting enzyme inhibitor and β-blockers was consistently below 50%, which is similar to the report from CABG patients in the Project of Ex-vivo Vein Graft Engineering via Transfection IV (PREVENT IV) trial. 28 The ) were still underway during the conduct of SYNTAX trial. It is therefore plausible that OMT was yet to gain full traction in the clinical arena. However, Borden et al 16 have also reported underuse of OMT in the National Cardiovascular Data Registry, and there has been little change in practice since publication of the COURAGE trial.
Lack of OMT was associated with a higher mortality and combined end point of death, MI, and stroke. Our message is consistent with previous data from the Medicine, Angioplasty, or Surgery Study (MASS II), 1 COURAGE, 2 BARI-2D, 33 and Surgical Treatment of Ischemic Heart Failure (STICH) 34 trials and provides a much-needed reinforcement of the importance of OMT after revascularization. 16 The most prominent effect of OMT was seen within the first year of revascularization. It is possibly due to the fact that the majority of adverse events occurred within the first year. However, the beneficial effect of OMT was sustained throughout the 5-year follow-up. CAD is a systemic disease involving multiple segments of the arterial tree 35 ; hence, the role of OMT is important for reducing or mitigating the risk of future cardiac events. 36 It is therefore likely that OMT exerted its beneficial effects by reducing the progression of coronary disease and the propensity for new plaque ruptures in noninstrumented or nonbypassed coronary segments. 36 Medications that reduce death or cardiovascular events (MI/stroke) in patients with CAD include antiplatelet drugs, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins. All of these agents have been shown to improve clinical outcomes and are recommended as secondary prevention therapy in patients with clinically evident CAD, 37, 38 including patients who have undergone CABG or PCI. 9, 10, 39 The role of individual agents to prevent adverse clinical events has been demonstrated in pharmacological trials of the individual drugs; however, the advantage of using all these agents in combination for all patients with CAD remains shrouded. As a result, antiplatelets and statins are generally prescribed to CAD patients, but the use of β-blockers and angiotensin-converting enzyme inhibitors is largely restricted to patients with additional indications, for example, hypertension, previous MI, or heart failure. Our findings suggest that OMT should be considered for all patients with complex CAD unless contraindicated. This recommendation is also supported by a post hoc analysis of patients undergoing CABG in the PREVENT IV trial (n=2970), in which individual components of OMT (except antiplatelet therapy) did not show a significant benefit but the combination (OMT) reduced mortality and MI at the 2-year followup. 28 Furthermore, our suggestion of not limiting these drugs to patients with CAD and other comorbidities is strengthened by data from the Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) study, in which patients discharged with β-blockers after cardiac surgery exhibited a substantially lower mortality at the 1-year follow-up, even those without a history of MI or heart failure. 40 However, it is prudent to highlight that SYNTAX patients had complex CAD and a significant proportion had other comorbidities, including hypertension, diabetes mellitus, and previous MI. There are reports showing no benefit of β-blockers in patients with stable CAD. 41 Hence, our findings may not Data were analyzed by use of a Cox regression model with OMT as the time-dependent covariate. CABG indicates coronary artery bypass graft; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction; OMT, optimal medical treatment; PCI, percutaneous coronary intervention; and PVD, peripheral vascular disease.
*HR for every 10-year increase in age >40 years. †Sex was a significant predictor only in PCI-treated patients. be applicable to patients with less complex or less extensive CAD without other comorbidities; the effect of OMT in this population needs to be explored further. On stratified analysis, there was a consistent trend that higher-risk patients such as the elderly, those with a high SYNTAX score or high EuroSCORE, patients with incomplete revascularization, those with an ejection fraction of <30%, patients with dyslipidemia, and those with chronic obstructive pulmonary disease may derive more benefit from OMT. In contrast, certain subgroups such as those with diabetes mellitus or peripheral vascular disease did not get a similar magnitude of benefit. This may reflect small numbers of patients in subgroups or a differential effect of medial therapy. However, the interaction values were not significant for any of the subgroups, suggesting that all patients may benefit from OMT. Higher-risk patients are likely to derive more benefit from OMT, but paradoxically, they are less likely to receive OMT. Results of the REACH registry have also suggested that patient subsets who are known to have poorer long-term outcomes are less likely to be on OMT. 29 Farkouh et al 42 analyzed data from diabetic patients in COURAGE, BARI-2D, and the Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) and found that only 8% of the FREEDOM, 18% of the COURAGE, and 23% of the BARI-2D patients achieved target for controlling blood pressure, cholesterol, diabetes mellitus, and smoking cessation. Many clinicians remain skeptical about prescribing β-blockers to patients with chronic obstructive pulmonary disease despite proven benefits. 43 Similarly, peripheral vascular disease is generally considered a relative contraindication for use of β-blockers on the basis of isolated studies or anecdotal findings, and there is no evidence to support that β-blockers are associated with worsening of peripheral vascular disease symptoms. 44, 45 Targeted interventions to improve the use of OMT in these high-risk subgroups may be beneficial [46] [47] [48] OMT is particularly underused in post-CABG patients, despite proven benefits. [11] [12] [13] [14] The use of OMT in CABG patients remained low in our study throughout the 5-year follow-up. Most of these patients are eventually followed up by family physicians and cardiologists, similar to the follow-up of PCI patients. It is possible that PCI patients had more hospitalization for angina and for repeat 26 However, it is also plausible that this difference in prescription of OMT represents misconceptions on the part of physicians and patients that OMT is not warranted after complete revascularization or differences in the process of care.
14 It is therefore pertinent to convey the importance of OMT to a wider clinical community, including cardiothoracic surgeons, interventional cardiologists, clinical cardiologists, general practitioners, and other healthcare providers, to ensure that these patients receive OMT regardless of revascularization strategy. This approach is likely to enhance the benefits achieved by either PCI or CABG.
Clinical Implications and Future Perspective
This study has several potential implications for clinical practice. It reinforces the importance of OMT use for patients with complex CAD undergoing revascularization. Considering greater benefits at early time points, it is best to ensure either that OMT is initiated before a patient is discharged after revascularization or that there is a clear follow-up plan to initiate these drugs. The importance of OMT should be emphasized to patients at each clinical encounter to improve compliance. 18 Moreover, hospital-and community-based programs such as the Get With The Guidelines and the Guidelines Applied in Practice initiative may help to improve the prescription of OMT and patient compliance. [46] [47] [48] Combining the OMT agents in a single tablet (polypill) may also improve adherence. 30 Further studies to understand the reason for OMT underuse and potential interventions to improve OMT use and adherence are needed.
Study Limitations
The main strengths of our study are the robustness and quality of data on medication at serial time points, derived from an allcomers clinical trial of patients with complex CAD. However, this is a post hoc analysis and has limitations inherent to any such analysis; indeed, the OMT and non-OMT groups were not matched at baseline. Use of drugs was assessed by selfreport from patients at clinic follow-up without external validation. 30, 46 Nevertheless, patient self-report has been shown to be a good method to assess adherence in clinical practice. 49 This study did not record the exact reason that patients did not receive a particular OMT drug class. Thus, our report did not separate legitimate nonprescription (resulting from intolerance or contraindication), physicians' nonadherence, and patients' nonadherence.
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Conclusions
The use of OMT remains suboptimal in patients with complex CAD requiring coronary intervention with PCI or CABG. Lack of OMT is associated with adverse clinical outcomes, including death, MI, and stroke. OMT should be considered for all patients with complex CAD treated with medical therapy, PCI, or CABG unless contraindicated.
